Trade

Watchlist

Portfolio

Message

Set Alert

BSE LIVE NSE LIVE 26 Aug, 2025 12:21 Volume Todays L/H More ×

Drug major Sun Pharma on Wednesday said it is open to enhancing its manufacturing footprint in the US amid the Trump administration imposing a 100 per cent tariff on branded and patented medicines.

In an analyst call, Richard Ascroft, the company’s CEO for the North America business, stated that the Mumbai-based drug maker already has a manufacturing footprint in the US.”We are kind of constantly assessing that manufacturing footprint, and we are open to considering this in the US in due time,” he said, when asked if the drug maker is open to localised manufacturing in the US in the wake of high tariffs.

The company is open for all options, he said withou

See Full Page